Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment source : Investor.alkermes.com save search
Alkermes Awarded Innovation Passport Designation by the MHRA (UK) for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
Published: 2023-01-17 (Crawled : 12:00) - investor.alkermes.com
ALKS | $23.76 -1.04% -0.97% 1.4M
|
Health Technology
|
| O: 2.31%
H: 2.43%
C: 2.15%
treatment designation melanoma nemvaleukin innovation
New National Survey of People Living with Bipolar I Disorder Provides Insights Into Disease-Related Challenges and the Treatment Journey
Published: 2022-01-06 (Crawled : 12:30) - investor.alkermes.com
ALKS | $23.76 -1.04% -0.97% 1.4M
|
Health Technology
|
| O: 0.52%
H: 3.76%
C: 3.29%
treatment order disease
Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa in Combination With Pembrolizumab for the Treatment of Platinum-Resistant Ovarian Cancer
Published: 2021-10-25 (Crawled : 11:00) - investor.alkermes.com
ALKS | $23.76 -1.04% -0.97% 1.4M
|
Health Technology
|
| O: 2.22%
H: 2.22%
C: 2.15%
treatment fda fda fast track fast track cancer nemvaleukin ovarian cancer fast track designation designation
Alkermes Announces FDA Approval of LYBALVI™ for the Treatment of Schizophrenia and Bipolar I Disorder
Published: 2021-06-01 (Crawled : 11:00) - investor.alkermes.com
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: 0.29%
H: 0.28%
C: -0.95%
ALKS | $23.76 -1.04% -0.97% 1.4M
|
Health Technology
|
| O: 0.79%
H: 1.4%
C: 1.31%
treatment fda schizophrenia fda approval approval
Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma
Published: 2021-03-11 (Crawled : 12:07) - investor.alkermes.com
ALKS | $23.76 -1.04% -0.97% 1.4M
|
Health Technology
|
| O: 1.56%
H: 1.79%
C: -0.1%
treatment fda drug designation
NIDA-Funded Study Evaluating Extended-Release Injectable Naltrexone Plus Bupropion for the Treatment of Methamphetamine Use Disorder Published in New England Journal of Medicine
Published: 2021-01-14 (Crawled : 12:08) - investor.alkermes.com
ALKS | $23.76 -1.04% -0.97% 1.4M
|
Health Technology
|
| O: 0.09%
H: 1.08%
C: 0.73%
treatment injection
FDA Advisory Committee Votes in Support of ALKS 3831 for the Treatment of Schizophrenia and Bipolar I Disorder
Published: 2020-10-09 (Crawled : 10:21) - investor.alkermes.com
ALKS | $23.76 -1.04% -0.97% 1.4M
|
Health Technology
| Email alert
Add to watchlist
fda schizophrenia treatment
Gainers vs Losers
| 59% | 41% |
Top 10 Gainers
AGBA | News | $1.03 157.5% 57.94% 120M
|
Finance
ZCMD | $1.45 5.84% 52.1% 2.3M
|
Commercial Services
TPET | $0.3279 -3.56% 28.48% 33M
|
n/a
GDHG | $0.263 21.76% 25.34% 1.3M
|
HOLO | $2.95 31.7% 22.49% 37M
|
UMAC | $1.55 0.65% 16.13% 3K
|
MTNB | $0.19 -1.04% 14.58% 950K
|
Health Technology
VLD 4 | $0.2638 -3.65% 13.27% 2.6M
|
Manufacturing
ALLR | $1.54 2.67% 11.76% 740K
|
n/a
MGLD 4 | $1.13 5.61% 10.62% 200
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.